%0 Journal Article %A Robert J. Hardwick %A James E. Truscott %A William E. Oswald %A Marleen Werkman %A Katherine E. Halliday %A Rachel L. Pullan %A Roy M. Anderson %T Individual adherence to mass drug administration in neglected tropical disease control: a probability model conditional on past behaviour %D 2020 %R 10.1101/2020.04.17.20069476 %J medRxiv %P 2020.04.17.20069476 %X We present a general framework which describes the systematic (binary) scenario of individuals either taking treatment or not for any reason, over the course of mass drug administration (MDA) — which we refer to as ‘adherence’ and ‘non-adherence’. The probability models developed can be informed by observed adherence behaviour as well as employed to explore how different patterns influence the impact of MDA programmes, by the use of mathematical models of transmission and control. We demonstrate the interpretative value of the developed probability model employing a dataset collected in the TUMIKIA project, a randomised trial of deworming strategies to control soil-transmitted helminths (STH) by MDA conducted in coastal Kenya. We stratify our analysis by age and sex, although the framework which we introduce here may be readily adapted to accommodate other stratifications. Our findings include the detection of specific patterns of non-adherence in all age groups to varying extents. This is particularly apparent in men of ages 30+. We then demonstrate the use of the probability model in stochastic individual-based simulations by running two example forecasts for the elimination of STH transmission employing MDA within the TUMIKIA trial setting with different adherence patterns. This suggested a substantial reduction in the probability of elimination (between 23-43%) when comparing observed adherence patterns with an assumption of independence, with important implications for programmes. The results here demonstrate the considerable impact and utility of considering non-adherence on the success of MDA programmes to control neglected tropical diseases (NTDs).Author summary Mass drug administration (MDA) is an important tool in the prevention of morbidity caused by various NTDs and in the reduction of their transmission. Due to a variety of social and behavioural reasons, many people will either not be offered or refuse such treatment, and if this behaviour is recurring at an individual level, then control measures may face a challenge in achieving their stated goals. Accurately describing the patterns of individual adherence or non-adherence to MDA control measures for NTDs from data, followed by their use in simulated scenarios is a relatively recent development in the study of NTDs. Past analyses assessing individual adherence have informed the approach we take in this work. However, we have sought to provide a framework which encapsulates as many types of adherence behaviour as possible to facilitate the assessment of impact in mathematical models of parasite transmission and control. Our example application to the TUMIKIA data highlights the importance of such a general framework as we find a dependence on past behaviour that may have been missed in standard statistical analyses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to sincerely thank Benjamin Collyer for careful reading of, and useful comments on, the manuscript. We extend our sincere thanks to the researchers who led data collection in Kenya during the TUMIKIA trial, including Paul M Gichuki, Stella Kepha, Carlos Mcharo, Stefan Witek-McManus, Mary W Karanja, Leah Musyoka, Lennie Mutisya, Tuva Safari, Idris Muye and Maureen Sidigu. Scientific oversight during data collection was provided by Charles Mwandawiro, Sammy Njenga and Simon Brooker. We also thank the many study participants who consented to provide stool samples, and the large study team, including managers, fieldworkers, laboratory technicians, and drivers. TUMIKIA was conducted in collaboration with the Government of Kenya Ministry of Health (MoH) and the Kwale County MoH, including Sultani Matendechero, Athuman Chiguzo, Hajara El-Busaidy and Redempta Muendo. Funding was received from the Bill & Melinda Gates Foundation, the Joint Global Health Trials Scheme of the Medical Research Council, the UK Department for International Development, the Wellcome Trust, and the Children's Investment Fund Foundation. RJH, JET, MW and RMA gratefully thank the Bill & Melinda Gates Foundation for research grant support via the DeWorm3 (OPP1129535) award to the Natural History Museum in London (http://www.gatesfoundation.org/). The views, opinions, assumptions or any other information set out in this article are solely those of the authors. All authors acknowledge joint Centre funding from the UK Medical Research Council and Department for International Development.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used were from the TUMIKIA project. %U https://www.medrxiv.org/content/medrxiv/early/2020/11/13/2020.04.17.20069476.full.pdf